PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Prev Res (Phila). Author manuscript; available in PMC 2009 September 1.
Published in final edited form as:
PMCID: PMC2720569
NIHMSID: NIHMS90338

NAD+-Dependent 15-Hydroxyprostaglandin Dehydrogenase Regulates Levels of Bioactive Lipids in Non–Small Cell Lung Cancer

Abstract

Elevated levels of procarcinogenic prostaglandins (PG) are foundin a variety of human malignancies including non–small cell lung cancer (NSCLC). Overexpression of cyclooxygenase-2 and microsomal prostaglandin synthase 1 occurs in tumors and contributes to increased PG synthesis. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the key enzyme responsible for metabolic inactivation of PGs, is down-regulated in various malignancies. The main objective of this study was to elucidate the effect of loss of 15-PGDH on levels of bioactive lipids in NSCLC. We found that levels of cyclooxygenase-2 and microsomal prostaglandin synthase 1 were commonly increased whereas the amount of 15-PGDH was frequently decreased in NSCLC compared with adjacent normal lung. Reduced expression of 15-PGDH occurred in tumor cells and was paralleled by decreased 15-PGDH activity in tumors. Amounts of PGE1, PGE2, and PGF, known substrates of 15-PGDH, were markedly increased whereas levels of 13, 14-dihydro-15-keto-PGE2, a catabolic product of PGE2, were markedly reduced in NSCLC compared with normal lung. Complementary in vitro and in vivo experiments were done to determine whether these changes in PG levels were a consequence of down-regulation of 15-PGDH in NSCLC. Similar to NSCLC, amounts of PGE1, PGE2, and PGF were markedly increased whereas levels of 13, 14-dihydro-15-keto-PGE2 were decreased in the lungs of 15-PGDH knockout mice compared with wild-type mice or when 15-PGDH was silenced in A549 lung cancer cells. Collectively, these data indicate that 15-PGDH is commonly down-regulated in NSCLC, an effect that contributes to the accumulation of multiple bioactive lipids in NSCLC.

Increased levels of procarcinogenic prostaglandins (PG) have been found in several human tumors including non–small cell lung cancer (NSCLC), which may reflect either increased PG synthesis or decreased catabolism (14). The synthesis of PGs from arachidonic acid requires two sequential enzymatic steps. Cyclooxygenase (COX) catalyzes the synthesis of PGH2 from arachidonic acid. There are two isoforms of COX: COX-1 is a housekeeping gene that is expressed constitutively in most tissues (5); COX-2 is an immediate-early response gene that is undetectable in most normal tissues but is rapidly induced by oncogenes, growth factors, cytokines, and tumor promoters (6, 7). Specific isomerases [e.g., microsomal prostaglandin synthase 1(mPGES-1)] then convert PGH2 to a variety of PGs including PGE1, PGE2, and PGF (7, 8). Because both COX-2 and mPGES-1 are commonly overexpressed in human malignancies (7, 913), enhanced synthesis is likely to explain, at least in part, the increase in PGs found in tumor tissue.

In theory, reduced catabolism of PGs may also contribute to elevated levels of PGs in human malignancies. The key enzyme responsible for metabolic inactivation of PGs is NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH; ref. 14). The human gene for 15-PGDH is located on chromosome 4 and codes for a 29-kDa enzyme that catalyzes the formation of 15-keto-PGs, which possess reduced biological activities compared with PGs (14, 15). 15-Keto-PGE2 is converted to 13, 14-dihydro-15-keto-PGE2 (14, 16). Reduced amounts of 15-PGDH have been reported in cancers of the colon, breast, lung, and bladder (1721). This decrease has been attributed to reduced gene expression because of either hypermethylation of the promoter or increased binding of repressive transcription factors to E-box elements in the promoter (21, 22). Recent evidence suggests that 15-PGDH is a tumor suppressor gene. For example, a marked increase in the formation of colon tumors occurred when 15-PGDH was knocked out in APCMin mice (23). Moreover, forced expression of 15-PGDH suppressed the growth of experimental lung tumors (17). Although 15-PGDH catabolizes a variety of PGs and lipoxins, its role in regulating the levels of these bioactive lipids in human malignancies is unknown. Given the established link between PGs and carcinogenesis, it is important to determine whether reduced expression of 15-PGDH contributes to the accumulation of bioactive PGs in tumor tissue.

In the present study, we first determined that the expression of enzymes involved in the synthesis (COX-2, mPGES-1) and catabolism (15-PGDH) of PGs was deregulated in NSCLC. Subsequently, levels of PGE1, PGE2, and PGF were found to be elevated in NSCLC versus normal lung. Complementary in vitro and in vivo studies suggested that loss of 15-PGDH expression in lung cells led to increased amounts of PGE1, PGE2, and PGF and reduced levels of 13, 14-dihydro-15-keto-PGE2, a pattern mimicking the profile in NSCLC versus adjacent normal lung. Taken together, these findings suggest that the observed increase in levels of multiple prostanoids in NSCLC reflects reduced catabolism, in addition to increased synthesis.

Materials and Methods

Materials

DMEM, fetal bovine serum, and LipofectAMINE 2000 were from Invitrogen. Rabbit anti-human polyclonal antibodies to mPGES-1 and deuterated eicosanoid standards were acquired from Cayman Chemical. Antibodies to 15-PGDH were from Novus Biologicals. Goat anti-human COX-2 antibody, antibody to β-actin, Lowry protein assay kits, arachidonate, butylated hydroxytoluene, citric acid, and EDTA were obtained from Sigma Chemical. Western blot analysis detection reagents (enhanced chemiluminescence) were from Amersham Biosciences. Nitrocellulose membranes were from Schleicher and Schuell. All high-performance liquid chromatography–grade solvents were purchased from Fisher Scientific Co. The Bradford protein assay kit was purchased from Bio-Rad.

Human specimens

Specimens were obtained at the time of surgery from patients with pulmonary adenocarcinoma or squamous cell carcinoma. Tissue samples were obtained from a nonnecrotic area of the tumor and from adjacent normal-appearing lung tissue. Samples were immediately snap frozen in liquid nitrogen and stored at −80°C until analysis. In addition, tissue sections for immunohistochemical staining were fixed in 10% buffered formalin and embedded in paraffin. The study was approved by the Committee on Human Rights in Research at Weill Cornell Medical College.

Animal model

Wild-type and 15-PGDH knockout mice were bred in the Case Western Reserve Animal Resource Center under a protocol approved by the Institutional Animal Care and Use Committee. Genotyping was carried out as described previously (24). At the time of sacrifice, lungs were snap frozen for future analysis.

Cell culture

The A549 human lung adenocarcinoma cell line was obtained from American Type Culture Collection and maintained in DMEM with low glucose, supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin.

Western blot analysis

Tissue or cell lysates were prepared by treatment with lysis buffer as described previously (25). Lysates were sonicated for 3 × 10 s on ice and centrifuged at 14,000 × g for 10 min at 4°C to remove the particulate material. The protein concentration of the supernatant was measured using the method of Lowry et al. (26). SDS-PAGE was done under reducing conditions on 12.5% polyacrylamide gels. The resolved proteins were transferred onto nitrocellulose sheets and then probed for COX-2, mPGES-1, 15-PGDH, and β-actin.

15-PGDH activity assay

Human lung tissue was suspended in 0.05 mol/L Tris buffer (pH 7.5), sonicated for 3 × 10 s on ice, and then centrifuged at 14,000 × g for 10 min at 4°C to remove the particulate material. 15-PGDH enzyme activity in tissue lysates was assayed by measuring the transfer of tritium from 15(S)-[15-3H]PGE2 to glutamate by coupling 15-PGDH with glutamate dehydrogenase as described previously (27).

Transient transfection

15-PGDH siRNA and nonspecific siRNA were obtained from Dharmacon. A549 cells were transfected with 100 pmol of siRNA using DharmaFECT transfection reagent according to the manufacturer's instructions. Following transfection for 24 h, the medium was changed. Twenty-four hours later, the media and cells were collected for analysis.

Immunohistochemistry

Formalin-fixed, paraffin-embedded tissue sections from surgical resection specimens containing primary lung squamous cell carcinomas and adenocarcinomas were evaluated for the presence and distribution of 15-PGDH. Four-micron-thick tissue sections of the tumor and nonneoplastic lung parenchyma from each case were immunohistochemically stained with the 15-PGDH rabbit polyclonal antibody as described below. Unstained tissue sections were baked, deparaffinized, and rehydrated on the VisionBio Systems BondMax autostainer (VisionBio Systems). Tissue sections were pretreated using the Vision-Bio Systems heat-induced epitope retrieval solution 1 and incubated with the primary antibody (1:1,625 dilution) for 25 min. The Refine Detection Kit supplied by the manufacturer (VisionBio Systems) was used to block endogenous peroxidase activity and enhance the staining reaction. Two sets of controls were done on unstained tissue sections from each case. The first control included incubation (1 h at room temperature) of the 15-PGDH antibody with the 15-PGDH protein (1:1 dilution; Novus Biologicals), dilution with VisionBio Systems diluent (1:800), and application of this solution to the tissue sections according to the methods described above. The second negative control involved replacing the primary antibody with immunoglobulin. Cytoplasmic staining for 15-PGDH in the lung tumors and nonneoplastic lung tissue was recorded as either absent (negative or weak staining) or present (moderate or strong intensity).

Determination of PG levels

PGs were extracted from cell culture medium using a solid-phase extraction method. Briefly, aliquots (10 µL) of 10% butylated hydroxytoluene and 20 µL of deuterated internal standards (100 ng/mL) were added to 1 mL of cell culture medium. The solution was applied to a Sep-Pak C18 cartridge (Waters Corp.) and PGs were eluted with 1 mL of methanol. The eluate was evaporated under a stream of nitrogen and the residue was reconstituted in 100 µL of a solution of methanol/10 mmol/L ammonium acetate (50:50, v/v). Analysis was carried out using liquid chromatography/tandem mass spectroscopy as detailed below.

PGs were extracted from human and murine lung tissue using a previously described method (28). Briefly, ~50 mg of frozen tissue were ground to a fine powder and homogenized with an Ultrasonic Processor (Misonix). An aliquot (100 µL) of homogenate was subjected to extraction with hexane/ethyl acetate (1:1). The upper organic layer was collected and the organic phases from three extractions were pooled and then evaporated to dryness under a stream of nitrogen. All extraction procedures were done at minimum light levels at 4°C. Samples were then reconstituted in 100 µL methanol/10 mmol/L ammonium acetate buffer, pH 8.5 (50:50, v/v), before liquid chromatography/tandem mass spectroscopic analysis. Protein concentration was determined by the method of Bradford according to the manufacturer's instructions.

Liquid chromatography/tandem mass spectroscopic analyses were done using a QuattroUltima mass spectrometer (Waters) equipped with an Agilent 1100 binary pump high-performance liquid chromatography system (Agilent) using a modified version of the method of Yang et al. (28). PGs of interest were chromatographically separated using a Luna 3-µm phenyl-hexyl 4.6 × 100 mm analytic column (Phenomenex). The mobile phase consisted of 10 mmol/L ammonium acetate (pH 8.5) and methanol using a linear methanol gradient that went from 50% to 60% for 10 min and then from 60% to 80% in 4 min. This was then increased to 100% methanol concentration over the next 6 min and kept at this condition for an additional 2 min to achieve chromatographic baseline resolution for the PGs of interest. The flow rate was 0.5 mL/min with a column temperature of 60°C. The mass spectrometer was operated in negative electrospray ionization mode with cone voltage of 40 V. Source temperatures were 125°C with desolvation gas temperature at 350°C. Collision-induced dissociation of the PGs was done using argon gas at a cell pressure of 1.6 × 10−3 Torr. PGs were detected and quantified by multiple reaction mode monitoring of the transitions m/z 351→271 for PGE2, m/z 355→275 for PGE2-d4, m/z 353→317 for PGE1, m/z 357→321 for PGE1-d4, m/z 353→309 for PGF, m/z 357→313 for PGF-d4, and m/z 351→333 for 13, 14-dihydro-15-keto-PGE2. The results are expressed as nanograms of PG per milligram of protein.

Statistics

Wilcoxon signed rank tests were used to analyze the 15-PGDH activity and PG levels in the paired human samples. Wilcoxon rank sum tests were used to analyze PG levels in the nonpaired samples in cell culture and mice (29). Statistical significance was set at 0.05 (two tailed). Means and SEs were also reported. Analyses were conducted with SAS 9.1 (SAS Institute, Inc.).

Results

Levels of 15-PGDH, COX-2, and mPGES-1 are commonly altered in NSCLC

Western blot analysis was used to evaluate the expression of COX-2, mPGES-1, and 15-PGDH in 19 paired (normal, tumor) samples of NSCLC (Fig. 1A and B). COX-2 (14 of 19, 74%) and mPGES-1 (17 of 19, 89%) were overexpressed in the majority of tumor samples. Conversely, levels of 15-PGDH (15 of 19, 79%) were reduced in most tumors. Consistent with the immunoblot findings, 15-PGDH activity was reduced in the majority of cases of NSCLC regardless of histology (Fig. 1C). Although COX-2 and mPGES-1 were commonly up-regulated and 15-PGDH down-regulated in NSCLC, there was considerable heterogeneity. For example, the magnitude of overexpression of COX-2 and mPGES-1 varied between cases. Moreover, up-regulation of mPGES-1 and down-regulation of 15-PGDH occurred in the absence of COX-2 overexpression in some cases [e.g., case 5 (Fig. 1A) or case 9 (Fig. 1B)]. Collectively, these results imply that the mechanisms controlling the expression of 15-PGDH, COX-2, and mPGES-1 must differ.

Fig 1
15-PGDH is down-regulated whereas COX-2 and mPGES-1 are overexpressedin NSCLC. Levels of COX-2, mPGES-1, and15-PGDH were measured by immunoblot analysis in 10 paired samples (N, normal; T, tumor) of adenocarcinoma (A) and 9 pairedsamples of squamous cell ...

Although 15-PGDH activity in lung contributes to the short half-life of PGE2 in blood (30), little is known about its cellular location. Hence, immunohistochemistry was carried out to localize 15-PGDH in lung tissue. Twenty surgical resection specimens containing primary lung squamous cell carcinomas (9 cases) and adenocarcinomas (11 cases) were evaluated. The nonneoplastic lung parenchyma showed cytoplasmic staining for 15-PGDH in pneumocytes in all 20 cases (Fig. 2A and B). The staining was specific because immunoreactivity was lost when antiserum to 15-PGDH was preadsorbed with 15-PGDH protein (Fig. 2C). All carcinomas showed decreased 15-PGDH staining (Fig. 2E–H), which was limited to <15% of the tumor tissue in all cases, and diminished intensity compared with the adjacent nonneoplastic lung parenchyma.

Fig 2
Immunohistochemical localization of 15-PGDH. Tissue sections from routinely processed lung resection specimens (A; H&E, ×200 magnification) showed strong cytoplasmic staining for 15-PGDH within nonneoplastic pneumocytes when incubated ...

PG levels are altered in NSCLC

Given the finding that enzymes involved in both the synthesis (COX-2 and mPGES-1) and catabolism (15-PGDH) of PGs are commonly deregulated in NSCLC, we next investigated the potential effect of these changes on PG levels. Twenty paired samples (10 adenocarcinomas and 10 squamous cell carcinomas) of NSCLC were analyzed for PG levels via liquid chromatography/tandem mass spectroscopy. Because the differences observed between tumor and normal were qualitatively similar for adenocarcinomas and squamous cell carcinomas, combined data are shown as NSCLC. The mean concentrations of PGE1, PGE2, PGF, and 13, 14-dihydro-15-keto-PGE2 are shown in Fig. 3. Marked increases in amounts of PGE1 (Fig. 3A), PGE2 (Fig. 3B), and PGF (Fig. 3C) were found in tumor tissue versus adjacent normal lung. Conversely, the amount of 13, 14-dihydro-15-keto-PGE2 (Fig. 3D), a catabolic product of PGE2, was significantly reduced from 0.16 to 0.01 ng/mg protein in the same tumor samples. All P values were <0.001 from Wilcoxon signed rank tests.

Fig 3
Levels of PGs are altered in NSCLC compared with adjacent normal-appearing lung. PGE1 (A), PGE2 (B), PGF (C), and 13, 14-dihydro-15-keto-PGE2 (D) were extracted from normal lung or NSCLC tissue homogenates and quantified, as described in Materials ...

Reduced expression of 15-PGDH contributes to deregulated levels of PGs in NSCLC

PGE1, PGE2, and PGF are all known substrates of 15-PGDH. To investigate whether reduced expression of 15-PGDH contributed to the increased levels of each of these PGs in NSCLC, we used both cellular and animal models. First, we used A549 cells, a cellular model that has been used extensively to evaluate the role of PGs in NSCLC (9, 17, 31). In an effort to mimic NSCLC, siRNA was used to knock down 15-PGDH and then PG production was measured. As shown in Fig. 4A, treatment of A549 NSCLC cells with siRNA led to a marked reduction in 15-PGDH protein. Consistent with the PG profile found in NSCLC versus adjacent normal-appearing lung (Fig. 3), silencing of 15-PGDH led to marked increases in the amounts of PGE1 (Fig. 4B), PGE2 (Fig. 4C), and PGF (Fig. 4D). These increases were associated with a reciprocal decrease in the production of 13, 14-dihydro-15-keto-PGE2 (Fig. 4E). Hence, siRNA-mediated suppression of 15-PGDH led to increased amounts of PGE1, PGE2, and PGF and reduced levels of 13, 14-dihydro-15-keto-PGE2, a pattern mimicking the profile in NSCLC versus adjacent normal-appearing lung (Fig. 3).

Fig 4
Silencing of 15-PGDH in A549 cells results in changes in PG production that mimic NSCLC. A, A549 cells were grown to 50% confluence before being transfected with either 15-PGDH siRNA or nonspecific (NS) siRNA for 24 h. Subsequently, the medium was changed ...

To further evaluate the role of 15-PGDH as a determinant of PG levels in the lung, we investigated the effects of knocking out 15-PGDH on levels of PGs in the murine lung. Consistent with the pattern found in NSCLC versus normal lung, knocking out 15-PGDH led to increased amounts of PGE1 (Fig. 5A), PGE2 (Fig. 5B), and PGF (Fig. 5C) in the murine lung. Conversely, amounts of 13, 14-dihydro-15-keto-PGE2 (Fig. 5D) were decreased in lungs of 15-PGDH knockout versus wild-type mice. All differences were statistically significant.

Fig 5
Knocking out 15-PGDH results in a PG profile in the murine lung that resembles the pattern found in human NSCLC. PGE1 (A), PGE2 (B), PGF (C), and 13, 14-dihydro-15-keto-PGE2 (D) were isolated from the lungs of wild-type and 15-PGDH knockout ...

Discussion

In this study, we found that levels of COX-2 and mPGES-1 were commonly increased whereas the amount of 15-PGDH was frequently decreased in NSCLC compared with adjacent normal lung. Reduced expression of 15-PGDH occurred in tumor cells and paralleled decreased 15-PGDH enzyme activity in tumors. Amounts of PGE1, PGE2, and PGF, known substrates of 15-PGDH, were markedly increased whereas levels of the catabolic metabolite 13, 14-dihydro-15-keto-PGE2 were markedly reduced in NSCLC compared with normal lung. An identical bioactive lipid profile was observed in the lungs of 15-PGDH knockout mice compared with wild-type mice or when 15-PGDH was silenced in A549 lung cancer cells. The fact that levels of PGE2 increased whereas amounts of 13, 14-dihydro-15-keto-PGE2, a catabolic metabolite, decreased is consistent with reduced expression of 15-PGDH. Taken together, these data strongly suggest that reduced expression of 15-PGDH in NSCLC contributes to the accumulation of multiple procarcinogenic prostanoids in NSCLC. To our knowledge, this is the first evidence that down-regulation of 15-PGDH contributes to the elevation of several procarcinogenic PGs in tumor tissue.

Several lines of evidence, beyond the finding of elevated levels of PGs in tumors, suggest a role for PGs in the development and progression of cancer. PGE2 can stimulate cell proliferation and motility while inhibiting apoptosis and immune surveillance (7, 9, 13, 32, 33). Importantly, PGE2 can also induce angiogenesis, at least in part, by enhancing the production of proangiogenic factors including vascular endothelial growth factor (34). Recently, PGE2 was found to induce an epithelial-to-mesenchymal transition, a process that is believed to be important for tumor metastasis (31). Notably, both PGE1 and PGF also have relevant procarcinogenic effects. Treatment with PGE1 increased the number of endothelial progenitor cells in the blood and bone marrow of mice and enhanced neoangiogenesis (35). The ability of PGE1 to induce vascular endothelial growth factor and suppress apoptosis may also contribute to tumor progression (36, 37). PGF also has multiple procarcinogenic effects. For example, PGF can stimulate the proliferation, motility, and invasiveness of cancer cells (38, 39). Similar to PGE1 and PGE2, PGF can induce vascular endothelial growth factor production and angiogenesis while inhibiting apoptosis (40, 41). Thus, down-regulation of 15-PGDH contributes to the accumulation of multiple PGs that are likely, in turn, to enhance tumor progression. In support of this notion, treatment with an anti-PGE2 monoclonal antibody or a selective COX-2 inhibitor suppressed the growth of transplantable NSCLC (42). Moreover, pharmacologic antagonists or genetic disruption of PG receptors can inhibit the progression of experimental NSCLC (43). In addition to PGE1, PGE2, and PGF, other eicosanoids including lipoxin A4, 12(S)-hydroxy-(5Z,8E,10E)-heptadecatrienoic acid, 15-hydroxyeicosatetraenoic acid, 5,15-dihydroxyeicosatetraenoic acid, and 8,15-dihydroxyeicosatetraenoic acid are also excellent substrates for 15-PGDH (44). Based on the current results, it will be of considerable interest to determine whether any of these other known substrates of 15-PGDH accumulate in NSCLC or other tumor types and contribute to tumor progression.

Although it is common for COX-2 and mPGES-1 to be overexpressed and 15-PGDH down-regulated in NSCLC, there is some heterogeneity. This suggests that the mechanisms controlling the expression of these enzymes are not identical. Both COX-2 and mPGES-1 can be induced by oncogenes or proinflammatory cytokines but the detailed control mechanisms are quite different (7, 11, 25). Several transcription factors, including activator protein 1, regulate the expression of COX-2 whereas early growth response factor 1 seems to be very important for stimulating mPGES-1 transcription (7, 25). Interestingly, the repressive transcription factors Snail and Slug can bind to conserved E-box elements in the 15-PGDH promoter and thereby inhibit transcription (22, 45). Alternatively, hypermethylation of the 15-PGDH promoter has been suggested to contribute to the loss of expression of 15-PGDH in breast cancer (21). Future studies will be needed to evaluate the mechanisms underlying the down-regulation of 15-PGDH expression in NSCLC. It is also important to consider shared regulatory mechanisms. Activation of epidermal growth factor receptor signaling can both induce COX-2 and suppress the expression of 15-PGDH (7, 22, 45). Possibly, activation of this pathway contributes to the up-regulation of COX-2 and down-regulation of 15-PGDH that are found in most cases of NSCLC. It will be worthwhile, therefore, to determine the effects of erlotinib, a selective inhibitor of epidermal growth factor receptor tyrosine kinase activity, on the levels of COX-2, 15-PGDH, and bioactive PGs in NSCLC or in intraepithelial neoplasia.

Selective COX-2 inhibitors, prototypic inhibitors of PG synthesis, are active in the treatment and prevention of colorectal adenomas and may have utility in the treatment of NSCLC (4649). However, chronic use of selective COX-2 inhibitors has been associated with increased risk of cardiovascular complications (50). The mechanisms underlying this toxicity are not fully understood, but inhibition of COX-2 results in the loss of all downstream PGs. It has been suggested that selective COX-2 inhibitors block the production of cardioprotective prostaglandin I2 by vascular endothelium without inhibiting COX-1–dependent platelet thromboxane A2 synthesis, supporting a prothrombotic mechanism. To improve the therapeutic index, alternate treatment strategies to suppress the levels or actions of PGs are being explored. Our data indicate that down-regulation of 15-PGDH contributes to the accumulation of procarcinogenic PGs in NSCLC. Hence, agents that induce 15-PGDH should normalize the levels of PGs in tumor or premalignant tissues. In this context, we note that pioglitazone and rosiglitazone, ligands of the peroxisome proliferator–activated receptor γ, were recently found to up-regulate 15-PGDH (51). Whether inducers of 15-PGDH will possess chemopreventive or antitumor activity and an acceptable therapeutic index will need to be evaluated.

Acknowledgments

We thank Paul Chadwick for his assistance in developing and carrying out the immunohistochemical techniques.

Grant support: NIH grant R25CA105012, Center for Cancer Prevention Research.

Footnotes

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids. 1996;54:83–94. [PubMed]
2. Bennett A, Carroll MA, Stamford IF, Whimster WF, Williams F. Prostaglandins and human lung carcinomas. Br J Cancer. 1982;46:888–893. [PMC free article] [PubMed]
3. McLemore TL, Hubbard WC, Litterst CL, et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1998;48:3140–3147. [PubMed]
4. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122:518–523. [PubMed]
5. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145–182. [PubMed]
6. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhancedin transformed mammary epithelial cells. Cancer Res. 1996;56:4424–4429. [PubMed]
7. Dannenberg AJ, Subbaramaiah K. Targeting cy clooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 2003;4:431–436. [PubMed]
8. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A. 1999;96:7220–7225. [PubMed]
9. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 1998;58:1208–1216. [PubMed]
10. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998;58:4997–5001. [PubMed]
11. Yoshimatsu K, Altorki NK, Golijanin D, et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res. 2001;7:2669–2674. [PubMed]
12. Yoshimatsu K, Golijanin D, Paty PB, et al. Inducible microsomal prostaglandin E synthase is over-expressed in colorectal adenomas and cancer. Clin Cancer Res. 2001;7:3971–3976. [PubMed]
13. Cohen EG, Almahmeed T, Du B, et al. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin Cancer Res. 2003;9:3425–3430. [PubMed]
14. Tai HH, Ensor CM, Tong M, Zhou H, Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 2002;68/69:483–493. [PubMed]
15. Pichaud F, Delage-Mourroux R, Pidoux E, Jullienne A, Rousseau-Merck MF. Chromosomal localization of the type-I 15-PGDH gene to 4q34-q35. Hum Genet. 1997;99:279–281. [PubMed]
16. Ensor CM, Tai HH. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. A key enzyme for the catabolism of prostaglandins. J Lipid Mediat Cell Signal. 1995;12:313–319. [PubMed]
17. Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis. 2005;26:65–72. [PubMed]
18. Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers. Proc Natl AcadSci U S A. 2004;101:17468–17473. [PubMed]
19. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005;280:3217–3223. [PMC free article] [PubMed]
20. Gee JR, Montoya RG, Khaled HM, Sabichi AL, Grossman HB. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol. 2003;21:266–270. [PubMed]
21. Wolf I, O'Kelly J, Rubinek T, et al. 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 2006;66:7818–7823. [PubMed]
22. Mann JR, Backlund MG, Buchanan FG, et al. Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res. 2006;66:6649–6656. [PubMed]
23. Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl AcadSci U S A. 2006;103:12098–12102. [PubMed]
24. Coggins KG, Latour A, Nguyen MS, Audoly L, Coffman TM, Koller BH. Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med. 2002;8:91–92. [PubMed]
25. Subbaramaiah K, Yoshimatsu K, Scherl E, et al. Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J Biol Chem. 2004;279:12647–12658. [PubMed]
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275. [PubMed]
27. Tong M, Tai HH. Induction of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells. Biochem Biophys Res Commun. 2000;276:77–81. [PubMed]
28. Yang P, Chan D, Felix E, et al. Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids. 2006;75:385–395. [PubMed]
29. Hollander M, Wolfe D. New York: Wiley-Liss; 1973. Nonparametric statistical methods.
30. Piper PJ, Vane JR, Wyllie JH. Inactivation of prostaglandins by the lungs. Nature. 1970;225:600–674. [PubMed]
31. Dohadwala M, Yang SC, Luo J, et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E2 induces transcriptional repressors ZEB1 and Snail in non-small cell lung cancer. Cancer Res. 2006;66:5338–5345. [PubMed]
32. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl1-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58:362–366. [PubMed]
33. Goodwin JS, Bankhurst AD, Messner RP. Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin producing suppressor cell. J Exp Med. 1977;146:1719–1734. [PMC free article] [PubMed]
34. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–716. [PubMed]
35. Gensch C, Clever Y, Werner C, Hanhoun M, Bohm M, Laufs U. Regulation of endothelial progenitor cells by prostaglandin E1 via inhibition of apoptosis. J Mol Cell Cardiol. 2007;42:670–677. [PubMed]
36. Weiss TW, Mehrabi MR, Kaun C, et al. Prostaglandin E1 induces vascular endothelial growth factor-1 in human adult cardiac myocytes but not in human adult cardiac fibroblasts via a cAMP-dependent mechanism. J Mol Cell Cardiol. 2004;36:539–546. [PubMed]
37. Siendones E, Jimenez-Gomez Y, Montero JL, Gomez-Diaz C, Villalba JM, Muntane J. PGE1 abolishes the mitochondrial-independent cell death pathway induced by d-galactosamine in primary culture of rat hepatocytes. J Gastroenterol Hepatol. 2005;20:108–116. [PubMed]
38. Qualtrough D, Kaidi A, Chell S, Jabbour HN, Williams AC, Paraskeva C. Prostaglandin F stimulates motility and invasion in colorectal tumor cells. Int J Cancer. 2007;121:734–740. [PMC free article] [PubMed]
39. Sales KJ, Milne SA, Williams AR, Anderson RA, Jabbour HN. Expression, localization, and signaling of prostaglandin F receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways. J Clin Endocrinol Metab. 2004;89:986–993. [PubMed]
40. Sales KJ, List T, Boddy SC, et al. A novel angiogenic role for prostaglandin F-FP receptor inter action in human endometrial adenocarcinomas. Cancer Res. 2005;65:7707–7716. [PMC free article] [PubMed]
41. Nishimura K, Setoyama T, Tsumagari H, et al. Endogenous prostaglandins E2 and F serve as an anti-apoptotic factor against apoptosis induced by tumor necrosis factor-α in mouse 3T3-L1 preadipocytes. Biosci Biotechnol Biochem. 2006;70:2145–2153. [PubMed]
42. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 2000;164:361–370. [PubMed]
43. Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res. 2006;66:9665–9672. [PubMed]
44. Ensor CM, Tai HH. 15-Hydroxyprostaglandin dehydrogenase. J Lipid Mediat Cell Signal. 1995;12:313–319. [PubMed]
45. Yang L, Amann JM, Kikuchi T, et al. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small cell lung cancer. Cancer Res. 2007;67:5587–5593. [PubMed]
46. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–1952. [PubMed]
47. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–884. [PubMed]
48. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol. 2003;21:2645–2650. [PubMed]
49. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B trial 30203. J Clin Oncol. 2008;26:848–855. [PubMed]
50. Solomon SC, Pfeffer MA, McMurray JJV, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028–1035. [PubMed]
51. Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol. 2007;71:1715–1720. [PubMed]